Three BMA awards for Karger Publishers

We are delighted to announce that three Karger titles received ‘Highly Commended’ awards by the British Medical Association in their prestigious 2016 Medical Book Competition:

**In the category ‘Internal Medicine’**

- **Tattooed Skin and Health**
  - Editors: Serup, J. (Copenhagen); Kluger, N. (Helsinki); Bäumler, W. (Regensburg)
  - X + 258 p., 110 fig., 85 in color, 25 tab., hard cover, 2015
  - www.karger.com/cupde

- **Retinal Pharmacotherapeutics**
  - Editors: Nguyen, Q.D. (Omaha, Nebr.); Rodrigues, E.B. (São Paulo); Farah, M.E. (São Paulo); Mieler, W.F. (Chicago, Ill.); Do, D.V. (Omaha, Nebr.)
  - XVI + 408 p., 83 fig., 71 in color, 33 tab., hard cover, 2016
  - www.karger.com/deoph

**In the category ‘Oncology’**

- **Immuno-Oncology**
  - Editors: Michielin, O.; Coukos, G. (Lausanne)
  - VI + 140 p., 8 fig., 5 in color, 11 tab., hard cover, 2015
  - www.karger.com/pritr

Karger titles which received awards in previous BMA Medical Book Competitions

- **Olszewski and Baxter’s Cytoarchitecture of the Human Brainstem**
  - Editors: J.A. Büttner-Ennever; A.K.E. Horn

- **Paediatric Bronchoscopy**
  - Editors: G. Cossu; A. Falco; A. Fernandez; G. Vesco

- **Macular Edema: A Practical Approach**
  - Editors: G. Cassani; J. Longhi; B. Laezza; G. Ferreira; E. Ferrarin
Guidelines for Authors

Submission
Before submission, please read the Guidelines for Authors for specific requirements for manuscript preparation. Manuscripts written in English are considered and should be submitted online at www.karger.com/che (a link leads you to the Submission Website).

Submission of an article implies author agreement with the below Conditions. To be considered for publication, all manuscripts must be accompanied by a cover letter signed by all authors stating that the work has not been published, nor is it under consideration elsewhere, and that all authors approve the submission.

A Copyright Transfer Form, available on the Submission Website, with the corresponding author’s original (hand-written) signature must be received by the editorial office. Please print and sign the form, and upload it during submission (or fax or scan and email) to make it legally binding.

Names, postal and e-mail addresses of 4 international experts in the appropriate area of research should accompany each manuscript. At the Editors’ discretion scientist(s) selected from this list may be invited to act as referee(s). Referees suggested should not be from the same institution as the author.

Presentation of manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (April 2010 version). Available from: http://www.icmje.org/).

In case of problems with submission, please contact:
che@karger.com
S. Karger AG – Medical and Scientific Publishers
Editorial Office “Chemotherapy”
Allschwilerstrasse 10
CH – 4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434

Conditions
All manuscripts are subject to editorial and peer review. Manuscripts are received with the explicit understanding that the work has not been published (wholly or in part), and is not under simultaneous consideration in any language elsewhere. Furthermore, all authors have made substantial contributions and confirm that they have seen and approve the manuscript submission. Submission of an article for publication implies the transfer of the copyright from the author to Karger Publishers upon acceptance. Accepted papers become the permanent property of Chemotherapy and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflict of Interest
Authors are required to disclose any sponsorship or funding arrangements related to the research presented in the manuscript and any possible conflicts of interest. A possible conflict of interest does not preclude consideration of a manuscript for publication, but the Editor might consider it appropriate to publish the disclosed information with the paper. All forms of support and financial involvement should be listed in the Acknowledgements section of the paper. The cover letter should certify that all forms of conflict of interest by all authors were clearly identified in the text.

Ethics
Research must comply with the guidelines for human studies and animal welfare regulations. Manuscripts reporting studies on human subjects should include evidence that the research was ethically conducted in accordance with the Declaration of Helsinki (World Medical Association; http://www.wma.net/en/30publications/10policies/b3/index.html). In particular, authors should state in the Materials and Methods section that subjects have given their informed written consent and that the study protocol was approved by an appropriate ethics committee. All patients should be identified by numbers or aliases, not by their real names. Authors should also state that animal experimentation was approved by an independent ethics committee. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. Karger Publishers defines plagiarism as reproduction of another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Sections
Authors should indicate in the cover letter which manuscript type is being submitted for publication:

Original Papers: Fully documented reports of original research that must describe full sets of significant, original experiments in current anti-infective and antitumor chemotherapy research. Abstract, Introduction, Materials and Methods, Results, and Discussion sections are required. Consideration for publication is based on originality, novelty, scientific soundness, and appropriate analysis (maximum 3,000 words, 80 references, plus tables/figures).

Reviews: Comprehensive, state-of-the-art papers covering a timely topic by experts in the field (maximum 4,000 words, plus tables/figures, references). Reviews are usually invited by the Editor but may be unsolicited. Authors are asked to contact the Editor-in-Chief before submission in order to avoid clashes with other pending reviews. All reviews are subject to peer review. An unstructured abstract of no more than 200 words is required.

Novel Insights from Clinical Practice: The journal only considers case reports that provide significant new insights into a clinical problem or an extremely unusual clinical course. Submissions can be based around a case or a number of similar cases. The most important aspect of the presentation is that it should provide a new perspective on a recognized clinical scenario or may represent an entirely new clinical condition. The novel aspects of the case(s) may be in the phenotype, the presentation, the investigation and/or the management. The manuscript should contain an unstructured abstract (maximum 150 words), introduction, case report and discussion section (maximum 2,000 words, maximum 2 tables or figures). Boxes containing bullet points on Established Facts (what is already known) and Novel Insights (new information gained) are required on the first page of the report. These should highlight the novelty of the clinical observation.

Short Communications: Short reports, brief laboratory observations, and preliminary communications can be submitted for accelerated publication under Short Communications. They must present new findings of sufficient importance to justify their accelerated acceptance. Such communications should represent complete, original studies and should be arranged in the same way as full length manuscripts (maximum 1,600 words).

Letters to the Editor: Letters to the Editor are encouraged if they directly concern articles recently published in this journal. If accepted, the Editor reserves the right to submit such letters to the authors of the articles concerned prior to publication in order to allow them to respond in the same issue of the journal. In exceptional cases, Letters to the Editor may also address data published in another journal or general subjects related to matters discussed in the journal. No abstract is required (maximum 1,200 words).

Arrangement
The preferred word processing program is MS-Word. The cover letter, the manuscript, the tables and the figures must be submitted in separate files. The manuscript file must contain all the text elements in the following order: title page, abstract and key words, main text, acknowledgments, references, table and figure legends. Tables and figures should be submitted as separate files according to the instructions below. Automatic line numbering should be used consecutively from the title page through to the final page. All pages should be numbered, starting from the title page, including tables, figure legends and figures.

Title page: The first page should contain the concise title of the article along with a short title for use as a running head, the full names of the authors and their affiliations (department, institute, hospital, university etc., where the work was conducted). The full postal address, telephone and fax numbers, as well as the e-mail address of the author to whom correspondence should be sent must be given at the bottom of the title page.

Key words: Please supply 3–10 key words that reflect the content of the paper.

Abstract: Each original paper needs an abstract of up to 250 words structured with subheadings as follows: Background/Aims, Methods, Results, Conclusions. Structured abstracts are not needed for Reviews and Novel Insights from Clinical Practice.

Footnotes: Footnotes should be avoided. When essential, they should be numbered consecutively and appear at the foot of the appropriate page.

Acknowledgements: Include all sources of funding for the research presented in the manuscript and substantive contributions of individuals regarding the research or manuscript. All possible conflicts of interest should also be given here.

Abbreviations: Abbreviations (with the exception of those clearly well-established in the field) should be explained when they are first used.

Units of Measurement: Measurements should be expressed in SI units wherever possible.

Drug names: Use generic names of drugs (first letter: lowercase) whenever possible. Registered trade names (first letter: uppercase) should be marked with the superscript registration symbol ® or ™ when they are first mentioned.

Tables and illustrations: Tables and figures must be numbered (e.g. Figure 1, Figure 2) and submitted as separate files. Tables require a heading and figures a legend, which must provide sufficient information for either to stand alone. Each figure and table must be cited in the text numerically. Tables should be in Word format. b/w half-tone and color figures must have a final resolution of 300 dpi after scaling to final size, line drawings 1,200 dpi. Color figures must be in RGB format. All figures should be in a common format such as PSD, TIF, PNG, EPS or WMF. Vector graphics should be in PPT, AI or EPS format.
Color Illustrations
Online edition: Color figures are reproduced free of charge. In the print version, the figures are reproduced in black and white. Referring to colors in the text and figure legends should be avoided.

Print edition: Up to 6 color figures per page can be integrated within the text at CHF 960.00 per page.

References
Identity references in the text using Arabic numerals (in square brackets). Do not alphabetize; number references sequentially in the order cited in the text. Material submitted for publication but not yet accepted should be referred to as [unpublished data] and should not be included in the reference list. All references listed should include only those publications which are cited in the text. Authors' surnames should be followed by their initials with no punctuation other than a period between initials, e.g. Nopp A, Cardell LO.

Authors should be cited only once, unless a longer description is necessary, e.g. Matschke and colleagues (2013) or Nopp et al. (2012). Personal communications should not be included in the reference list. The reference list should include only those references which are cited in the text. Authors should be alphabetized (if not possible include at least 3 authors followed by et al). Abbreviate journal names according to the list of journals indexed for MEDLINE on the NLM website. Also see International Committee of Medical Journal Editors: Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.ICMJE.org).

Examples


Reference Management Software: The use of EndNote is recommended to facilitate formatting of citations and reference lists. The journal output style can be downloaded from http://endnote.com/downloads/styles.

Supplementary Material and Multimedia Files
Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 Mb in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.

English Language Editing
For authors whose native language is not English, use of a professional language editing service prior to submission can help to avoid delays with the review process.

Digital Object Identifier (DOI)
A DOI number will be available as a unique identifier on the title page of each article. DOIs are useful for identifying and citing articles published online without volume or issue information (for more information, see www.doi.org).

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

• Be used for noncommercial purposes only
• Be linked to the final version on www.karger.com

Include the following statement:
“This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/doi/insert DOI number.”

It is the author’s responsibility to fulfill these requirements. If papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article. Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf (see Funding Organizations (NIH etc.)).

For self-archiving Author's Choice (Gold Open Access) articles, see Author's Choice.

Author's Choice
Karger’s Author’s Choice service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

• Include the following statement:
“[The final, published version of this article is available at http://www.karger.com/doi/insert DOI number].”

It is the author’s responsibility to fulfill these requirements. For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s Choice, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCVK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Copy Editing
Manuscripts accepted for publication by Karger Publishers are subject to copy editing.

Proofs
An email containing a link to download the proofs will be sent to the corresponding author. Proofs should be returned within 48 hours. Alterations made in proofs, other than the correction of printer’s (introduced) errors, are charged to the author and may require editorial approval.

Page Charges
There is no page charge for papers of 3 or fewer printed pages (including tables, illustrations and references). Authors are charged CHF 325.00 for each additional complete or partial printed page.

Reprints
An order form with a price list can be requested when returning the corrected proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

KARGER
E-Mail karger@karger.com
www.karger.com

© 2017 S. Karger AG, Basel

The Guidelines for Authors are available at: www.karger.com/che_Guidelines
Contents

See the journal website for contents
Acta Haematologica is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.

Acta Haematologica
Founded: 1948
Category: Clinical and Basic Research
Field of Interest: Hematology

Listed in bibliographic services, including:
PubMed/MEDLINE, Web of Science, Google Scholar, Scopus, Embase

2017: Volumes 137, 138
4 issues per volume
Language: English
ISSN 0001–5792
e-ISSN 1421–9662

Selected contributions
• Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy: Muchtar, E.; Buadi, F.K.; Dispenzieri, A.; Gertz, M.A. (Rochester, Minn.)
• Autologous Stem Cell Transplantation as the First-Line Treatment for Peripheral T Cell Lymphoma: Results of a Comprehensive Meta-Analysis: Yin, J.; Wei, J.; Xu, J.H.; Xiao, Y.; Zhang, Y.C. (Wuhan)
• Bone Marrow Aspiration: A Randomized Controlled Trial Assessing the Quality of Bone Marrow Specimens Using Slow and Rapid Aspiration Techniques and Evaluating Pain Intensity: Grønkjær, M.; Hasselgren, C.F.; Østergaard, A.S.L.; Johansen, P.; Korup, J.; Bøgsted, M.; Bilgrau, A.E.; Jensen, P. (Aalborg)
• Biosimilar Epoetin Zeta in Oncology and Haematology: Development and Experience following 6 Years of Use: Michallet, M. (Pierre Bénite); Losem, C. (Neuss)
• Treatment of Patients with Multiple Myeloma: An Overview of Systematic Reviews: Kumar, A.; Galeb, S.; Djulbegovic, B. (Tampa, Fla.)
• Cardiotoxicity and Cardioprotection in Childhood Cancer: Lipshultz, S.E. (Miami, Fla./Detroit, Mich.); Sambatakos, P.; Maguire, M.; Karnik, R.; Ross, S.W.; Franco, V.J.; Miller, T.L. (Miami, Fla.)
• The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis: Hu, C.; Deng, C.; Zou, W.; Zhang, G.; Wang, J. (Changsha)

More information at www.karger.com/aha
Antimicrobial Section

Original Papers

1 Antimicrobial Susceptibility among European Gram-Negative and Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation and Surveillance Trial (2004–2014)
Rodloff, A.C. (Leipzig); Dowzicky, M.J. (Collegeville, Pa.)

12 Characterization of Integrons and qnr Genes in Proteaeae from a Teaching Hospital in China
Cao, J. (Xi'an/Wenzhou); Li, M. (Hangzhou); Xu, C.; Zhou, T.; Du, J.; Sun, Y. (Wenzhou); Qin, L. (Ningbo); Xu, J. (Xi'an)

34 Characterization of Integrons and Sulfonamide Resistance Genes among Bacteria from Drinking Water Distribution Systems in Southwestern Nigeria
Adesoji, A.T. (Dutsin-Ma); Ogunjobi, A.A. (Ibadan); Olatoye, I.O. (Ibadan/Pullman, Wash.)

Anticancer Section

Reviews

43 Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy
He, C.; Li, L. (Changsha); Guan, X. (Seattle, Wash.); Xiong, L.; Miao, X. (Changsha)

62 New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin
Mahlberg, R. (Trier); Lorenzen, S. (Munich); Thuss-Patience, P. (Berlin); Heinemann, V. (Munich); Pfeiffer, P. (Odense); Möhler, M. (Mainz)

Original Papers

23 Hemoglobin Value Is the Most Important Factor in the Development of Hand-Foot Syndrome under the Capecitabine Regimen
Naito, M. (Takatsuki/Suita); Yamamoto, T.; Hara, S. (Suita); Shimamoto, C. (Takatsuki); Miwa, Y. (Suita)

30 GEMOX: An Active Regimen for the Treatment of Luminal and Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Rizzi, A.; Aroldi, F.; Bertocchi, P.; Prochilo, T.; Mutti, S.; Savelli, G. (Brescia); Fraccon, A.P. (Peschiera); Zaniboni, A. (Brescia)

71 Comparison of the Therapeutic Efficacy of the Early and the Delayed Use of Vinorelbine-Based Regimens for Patients with Advanced Breast Cancer
Wang, Y.; Liu, J.; Jia, W.; Li, S.; Rao, N.; Su, F.; Liu, Q.; Yao, H. (Guangzhou)

Novel Insights from Clinical Practice

19 Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma

54 Germ Cell Tumor Targeting Chemotherapy in Gastric Adenocarcinoma with an Endodermal Sinus Tumor Component: A Case Report
Choi, J.E.; Choe, A.R.; Yoon, S.E.; Nam, E.M. (Seoul); Park, H. (Goyang); Lee, K.E. (Seoul)

58 Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant

80 Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
Huang, C.-W.; Yeh, Y.-S.; Ma, C.-J.; Tsai, H.-L.; Chen, C.-W.; Huang, M.-Y.; Lu, C.-Y.; Wu, J.-Y.; Wang, J.Y. (Kaohsiung)